O

Oculis S.A.

22 employees

Oculis is a clinical-stage biopharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.

Basic info

Industry

biotechnology

Sectors

Biotechnology
pharmaceutical
Health Care
Biotech
ophthalmology
Pharmaceutical
drug delivery

Date founded

2017

Funding rounds raised

Total raised

$91M

from 15 investors over 15 rounds

O

Oculis S.A. raised $91M on March 3, 2023

Investors: Tekla Capital Management, Earlybird Venture Capital and VI Partners AG

O

Oculis S.A. raised $57M on May 4, 2021

Investors: Nan Fung Life Sciences, Tekla Capital Management, VI Partners AG, BioVeda China Fund, Earlybird Venture Capital and Wille Finance

O

Oculis S.A. raised $16M on January 4, 2019

Investors: Nan Fung Life Sciences, Tekla Capital Management and -

O

Oculis S.A. raised $21M on January 4, 2018

Investors: Bay City Capital and -

O

Oculis S.A. raised undisclosed on August 16, 2016

Investors: -

FAQ